Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Dec 16, 2022 12:24pm
101 Views
Post# 35176021

RE:RE:RE:RE:RE:About craighenry

RE:RE:RE:RE:RE:About craighenryAbout the Chiesi deal, that name was never mentioned to me by Bioasis. But the Chiesi name was bandied about for a long time, since before DrDR became CEO. I considered it speculation, just as many pharmas are discussed. It's a long list of pharmas that have been discussed.

In any event, I had no advanced notice of a Chiesi deal, although I did have a conversation with DrDR in February about things.

She asked me to write a long background piece about Bioasis for two outfits that were going to cover news of a Bioasis deal that was imminent. She did not tell me who the other company was. I told her that the name "Chiesi" was going around. She didn't confirm that in any way. I think one of the outfits  that the piece was for was Zacks. I didn't read either of their coverages.

Anyway, the name Chiesi was out there. I was being asked about them so I did a little DD about them. I would rather have seen a deal with a larger, publicly-traded pharma because it would have made more industry news. The news was delayed until June, because of Covid, if I recall.

I think it posible that Chiesi, like most things that DrDR announced, came from first intitiatives by Mark Day. He got around pretty good. It's funny how things work out but he may have been the "oasis" in Bioasis.

What did Colwell Capital signal to shareholders before this deal was announced? "You gotta be there"? Two more people told me yesterday about that.

It's so easy to signal something without having knowledge of it, or intent to do it.

jd

<< Previous
Bullboard Posts
Next >>